Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT03559270 |
| Consolidated Lead Sponsor | Eli Lilly and Company |
| Therapeutic Condition Cohort | Immunology, Rheumatology, and Dermatology |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | TERMINATED |
| Registered Enrollment | 374 participants (ACTUAL) |
| Registered Start Date | 2018-06-27 |
| WhyStopped Classification | Unspecified |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| University of Alabama at Birmingham | Birmingham, AL | Open Hospital Dossier -> |
| California Dermatology & Clinical Research Institute | Encinitas, CA | Open Hospital Dossier -> |
| First OC Dermatology | Fountain Valley, CA | Open Hospital Dossier -> |
| Center for Dermatology Clinical Research, Inc. | Fremont, CA | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.